Literature DB >> 33894839

Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.

Jacob E Choby1, Tugba Ozturk1, Sarah W Satola2, Jesse T Jacob2, David S Weiss3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33894839      PMCID： PMC8175093          DOI： 10.1016/S1473-3099(21)00194-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  5 in total

1.  Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae.

Authors:  Victor I Band; Emily K Crispell; Brooke A Napier; Carmen M Herrera; Greg K Tharp; Kranthi Vavikolanu; Jan Pohl; Timothy D Read; Steven E Bosinger; M Stephen Trent; Eileen M Burd; David S Weiss
Journal:  Nat Microbiol       Date:  2016-05-09       Impact factor: 17.745

2.  Carbapenem-Resistant Klebsiella pneumoniae Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection.

Authors:  Victor I Band; Sarah W Satola; Eileen M Burd; Monica M Farley; Jesse T Jacob; David S Weiss
Journal:  mBio       Date:  2018-03-06       Impact factor: 7.867

3.  Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant Enterobacterales in the United States.

Authors:  Victor I Band; Sarah W Satola; Richard D Smith; David A Hufnagel; Chris Bower; Andrew B Conley; Lavanya Rishishwar; Suzanne E Dale; Dwight J Hardy; Roberto L Vargas; Ghinwa Dumyati; Marion A Kainer; Erin C Phipps; Rebecca Pierce; Lucy E Wilson; Matthew Sorensen; Erik Nilsson; I King Jordan; Eileen M Burd; Monica M Farley; Jesse T Jacob; Robert K Ernst; David S Weiss
Journal:  mBio       Date:  2021-01-26       Impact factor: 7.867

4.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421

5.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.

Authors:  Meredith A Hackel; Masakatsu Tsuji; Yoshinori Yamano; Roger Echols; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191
  5 in total
  7 in total

Review 1.  In search for a synergistic combination against pandrug-resistant A. baumannii; methodological considerations.

Authors:  Stamatis Karakonstantis; Petros Ioannou; Diamantis D Kofteridis
Journal:  Infection       Date:  2022-01-04       Impact factor: 3.553

Review 2.  Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance.

Authors:  Stamatis Karakonstantis; Maria Rousaki; Evangelos I Kritsotakis
Journal:  Antibiotics (Basel)       Date:  2022-05-27

3.  Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Leonildi; Leonardo Della Sala; Alessandra Vecchione; Simona Barnini; Alessio Farcomeni; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

Review 4.  Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.

Authors:  Chuanhai Wang; Deqing Yang; Yifan Wang; Wentao Ni
Journal:  Front Pharmacol       Date:  2022-04-12       Impact factor: 5.988

Review 5.  Antibiotic Heteroresistance in Klebsiella pneumoniae.

Authors:  Karolina Stojowska-Swędrzyńska; Adrianna Łupkowska; Dorota Kuczyńska-Wiśnik; Ewa Laskowska
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

6.  Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials.

Authors:  Patrice Nordmann; Ryan K Shields; Yohei Doi; Miki Takemura; Roger Echols; Yuko Matsunaga; Yoshinori Yamano
Journal:  Microb Drug Resist       Date:  2022-01-24       Impact factor: 2.706

Review 7.  Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam.

Authors:  Adam B Shapiro; Samir H Moussa; Sarah M McLeod; Thomas Durand-Réville; Alita A Miller
Journal:  Front Microbiol       Date:  2021-07-19       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.